Bemcentinib

DB12411InvestigationalSmall molecule

Bemcentinib has been investigated for the treatment of Non-Small Cell Lung Cancer.

Mechanism: Pharmacologically active on Spike glycoprotein and Tyrosine-protein kinase receptor UFO
Curator reviewed
Formula / weight: C₃₀H₃₄N₈ · 506.658 g/mol (avg)
Code names: BGB-324 · R428

Resolves to

Compound

Structure

InChIKeyKXMZDGSRSGHMMK-VWLOTQADSA-NSMILESNC1=NC(NC2=CC=C3CC[C@@H](CCC3=C2)N2CCCC2)=NN1C1=CC2=C(N=N1)C1=CC=CC=C1CCC2

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bemcentinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.